Super short membrane-active lipopeptides inhibiting the entry of influenza A virus  by Wu, Wenjiao et al.
Biochimica et Biophysica Acta 1848 (2015) 2344–2350
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemSuper short membrane-active lipopeptides inhibiting the entry of
inﬂuenza A virusWenjiao Wu 1, Jingyu Wang 1, Dongguo Lin, Linqing Chen, Xiangkun Xie, Xintian Shen, Qingqing Yang,
Qiuyi Wu, Jie Yang, Jian He ⁎, Shuwen Liu ⁎
School of Pharmaceutical Sciences, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou 510515, PR China⁎ Corresponding authors.
E-mail addresses: jianhe@smu.edu.cn (J. He), liusw@s
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.bbamem.2015.06.015
0005-2736/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 27 February 2015
Received in revised form 25 May 2015
Accepted 10 June 2015
Available online 16 June 2015
Keywords:
Inﬂuenza A virus
Virus entry inhibitor
Short lipopeptide
Membrane fusion
Fusion inhibition
Virus–cell fusionInﬂuenza A viruses (IAV) are signiﬁcant pathogens that result in millions of human infections and impose a sub-
stantial health and economic burdens worldwide. Due to the limited anti-inﬂuenza A therapeutics available and
the emergence of drug resistant viral strains, it is imperative to develop potent anti-IAV agents with different
mode of action. In this study, by applying a pseudovirus based screening approach, two super short
membrane-active lipopeptides of C12-KKWK and C12-OOWO were identiﬁed as effective anti-IAV agents with
IC50 value of 7.30 ± 1.57 and 8.48 ± 0.74 mg/L against A/Puerto Rico/8/34 strain, and 6.14 ± 1.45 and 7.22 ±
0.67 mg/L against A/Aichi/2/68 strain, respectively. The mechanism study indicated that the anti-IAV activity of
these peptides would result from the inhibition of virus entry by interacting with HA2 subunit of hemagglutinin
(HA). Thus, these peptides may have potentials as lead peptides for the development of new anti-IAV therapeu-
tics to block the entry of virus into host cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Inﬂuenza A viruses are enveloped RNA viruses belonging to the
family of Orthomyxoviridae [1]. They cause seasonal epidemics and
reoccurring pandemics of inﬂuenza,which pose a signiﬁcant andworld-
wide threat to human health. This threat has occurred periodically since
the spread of the highly pathogenic H5N1 avian inﬂuenza in 1997 [2].
The morbidity caused by annual inﬂuenza epidemics is estimated to
be in the range of 3 to 5 million cases, and the mortality is up to half
a million [3], thus bringing into an urgent need for the new anti-
inﬂuenza A viral agents to provide a ﬁrst line of defense against such
an outcome. Vaccination has been an effective approach in prevention
of inﬂuenza A viral infection. However, due to the constant antigenic
drift and the emergence of new subtypes of current virus, inﬂuenza A vi-
ruses remain to be persistent threats to mankind [4]. Particularly, in the
face of a pandemic outbreak, vaccine production always lags a few
months behind the emergence of the new virus [5]. Therefore, antiviral
chemotherapy remains to play an important role in the prevention and
treatment of inﬂuenza.
Currently, two classes of antivirals are clinically available to control
human inﬂuenza virus infections. They are (a) neuraminidase (NA) in-
hibitors, such as oseltamivir, zanamivir and peramivir, which inhibit
virus budding [5], and (b) viral matrix 2 ion protein (M2) inhibitors.mu.edu.cn (S. Liu).The M2 ion channel blockers such as amantadine and rimantadine in-
hibit viral uncoating by blocking the proton channel activity of the inﬂu-
enza A viral M2 protein [6]. These drugs have been used for many years
and the appearance of drug resistant strains has been reported [7]. In
addition, adamantanesmay be associatedwith neuropsychiatric side ef-
fects such as insomnia, confusion, and hallucinations, etc [8]. These
drawbacks highlight the urgency to develop new antiviral drugs that ef-
fectively target other viral proteins or cellular factors involved in the in-
ﬂuenza virus life cycle [6,9].
In regard to the inﬂuenza virus-life cycle, several events are involved
and some of them have been reported as potential targets for chemo-
therapeutic intervention. These are including inhibition of the essential
functions of the three viral surface glycoproteins: the hemagglutinin
(HA), involved in cell entry and fusion; the M2 ion channel protein, in-
volved in virus uncoating; and the neuraminidase (NA), related to the
release of new virus particles [9]. Among them, virus attachment medi-
ated byHA is the ﬁrst step for viral infection [10,11]. TheHAof inﬂuenza
virus is a surface protein and is presented as a homo-trimer with each
monomer consisting of two chains, HA1 and HA2, linked by a single di-
sulﬁde bond. In the events of virus entry, the HA1 subunit is responsible
for binding the virus to host cell of sialic acid-containing receptors,
while the HA2 subunit is responsible for fusion [12,13]. Thus, the HA in-
cluding HA1 and HA2 subunits is a potential target for antiviral drug to
intervene thereby blocking the entry of viruses into host cells.
Based on this progress, in this work, we employed a pseudo-
virus based “entry inhibitor” screening approach to evaluate our
membrane-active lipopeptide library for potent antiviral agents that
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virus was constructed as previously reported by employing the plas-
mids encoding hemagglutinin glycoprotein (HA) and neuraminidase
protein (NA) into HIV backbone [14], while the lipopeptide library
was designed by combining the knowledge that (a) arginine, lysine
and tryptophan rich peptides always possess potent antimicrobial activ-
ities, and (b) lipopeptides are a class of antimicrobial peptides
possessing high potencies [15]. As a consequence of initial screening,
two very short lipopeptides of C12-KKWK and C12-OOWO being able
to inhibit the infectivity of H5N1 inﬂuenza A pseudovirus were identi-
ﬁed. Their antiviral activities were then conﬁrmed by testing the viral
strains of inﬂuenza A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68
(H3N2). Furthermore, the structures of C12-KKWK and C12-OOWO
were optimized which led to the identiﬁcation of more potent peptides
of C20-KKWK and C20-OOWO as effective inﬂuenza A virus “entry in-
hibitors”. In this paper, we report on the antiviral activity and the
mode of action of these peptides.
2. Materials and methods
2.1. Organisms and cell culture
Madin Darby Canine Kidney (MDCK) cells and 293T cells were
obtained from the American Type Culture Collection (ATCC) and cells
were grown in Dulbecco's Modiﬁed Eagle Medium (DEME, Gibco)
containing glutamine, supplemented with 10% fetal bovine serum
(FBS). Inﬂuenza A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2)
viruses stockwere propagated in the allantoic cavities of 9-day-old em-
bryonated hen eggs at 37 °C. The allantoic ﬂuid was harvested, clariﬁed
by low-speed centrifugation and stored at−80 °C. The virus titer was
determined through the analysis of the 50% tissue culture infective
dose (TCID50) onMDCK cells and evaluated by using themethod devel-
oped by Reed-Muench formula [16].
2.2. Peptide synthesis
All methods for peptide synthesis in this study have been previously
described [15]. Brieﬂy, peptides were synthesized on an ABI 433A
peptide synthesizer with 0.1 mmol scale by using standard
9-ﬂuorenylmethoxy carbonyl (Fmoc) solid phase protocols on Rink
Amide MHBA resin. The peptide chain assembly was catalyzed by
using HBTU/HOBt coupling chemistry with four-fold excess, except for
lipid chain, where ten-fold excess was employed. All peptides were
cleaved from the resin by using cleavage cocktail containing 87.5%
triﬂuoroacetic acid, 2.5% ethanedithiol, 5% thioanisole and 5% deionized
water (2–3 h, room temperature). The molecular weight of each pep-
tide was conﬁrmed by electrospray ionization mass spectrometry
(ESI-MS, Waters), and the purity of peptide was analyzed with
Shimadazu 10A HPLC instrument on a C18 column (250 × 4.6 mm,
Sepax Technologies, US). The HPLC is as follows: ﬂow rate, 0.8 mL/min;
mobile phase, solvent A: water (0.075% triﬂuoroacetic acid), B: acetonitrile/
methonal (1:1 supplementarywith 0.075% triﬂuoroacetic acid); gradient:
15% to 20% B (2min), 20% to 60% B (10 min), 60% to 80% B (6min), 80%
to 90% B (6min) with the ﬁnal products purity of N90% (Fig. S1), other-
wise puriﬁed with HPLC if necessary.
2.3. Measurement of the inhibitory activity on the entry of
H5N1 pseudovirus
The plasmids encodingHA andNA of A/Thailand/Kan353/2004were
used to prepareH5N1 pseudovirus. The protocolwas adopted as report-
ed before [14]. Brieﬂy, 293T cells (75–95% conﬂuent) were co-
transfected with 1 μg HA plasmid, 1 μg NA plasmid, and 3 μg HIV back-
boneplasmid (pNL4-3.luc.R−E−), which contains an Env andVpr defec-
tive, luciferase-expressing HIV-1 genome, into 6-well plate, using
polyethylenimine (PEI) as the transfection reagent. After transfectionfor 48 h, the culture supernatants were harvested and centrifuged at
2000 rpm for 5 min. Aliquots were stored at −80 °C. The titer of
pseudovirus was quantitated by the luciferase assay.
To measure the inhibitory effects of tested peptides, MDCK cells
(1 × 104/well) were seeded in 96-well plates and grown overnight.
The peptides in various concentrations were incubated with pseudo-
typed particles for 30 min at 37 °C. Subsequently, the virus–peptide
mixture was transferred to the cells and incubated for another 48 h.
Cells were washed with PBS and lysed with the lysing reagent included
in the luciferase kit (Promega, Madison, WI). Aliquots of the cell lysates
were transferred to 96-well ﬂat bottom luminometer plates, followed
by the addition of luciferase substrate. The luciferase activity was mea-
sured in a microplate luminometer (Genios Pro Tecan, US). CL-385319
at 50 μM was used as a positive control, while wells without peptides
as a negative control [14].
2.4. Virus titer reduction assay
Antiviral activities of peptides were further assessed by the virus
titer reduction assay as reported previously with minor modiﬁcations
[17,18]. Brieﬂy, MDCK cells were seeded into a 96-well plate at
2 × 104 per well and incubated overnight until grown up to 90% conﬂu-
ence. Inﬂuenza A/Puerto Rico/8/34 (H1N1) andA/Aichi/2/68 (H3N2) vi-
ruses at 100 TCID50 were respectively mixed with peptides at the
indicated concentrations and incubated at 37 °C for 30 min. Subse-
quently, the virus–peptide mixtures were added to the cells and incu-
bated for another 30 min. Then cells were washed twice with PBS to
remove unabsorbed virus, followed by the addition of serum free
DMEM supplemented with 1 mg/L TPCK-trypsin and 0.2% BSA. At 48 h
post-infection, the inhibition of viral replication was determined by
measuring the virus titer in the supernatant.
To measure the inhibition of viral replication, 50 μL supernatant was
added to a 96-well black plate. Then added 20 μL H2O and 30 μL
4-MUNANA substrate dissolved in dilute buffer (33 mM MES pH =
3.5 and 4 mM CaCl2) at a ﬁnal concentration of 20 μM, and the mixture
was further incubated for 1 h at 37 °C in the dark. The reaction was
terminated with 150 μL 14 mM NaOH (dissolved in 83% ethanol) and
the ﬂuorescence of the mixture was recorded at the excitation wave-
length of 340 nm and emission wavelength of 440 nm with the multi-
functional microplate reader (SpectraMax M5, US). The inhibition
ratio was determined by using the equation:
Inhibitory activity %ð Þ ¼ Fvirus−Fsample
 
Fvirus−Fsubstrateð Þ
 100%
where Fvirus is the ﬂuorescence of the supernatants of the virus control,
Fsubstrate is the ﬂuorescence of the substrate control (buffer and sub-
strate), and Fsample is the ﬂuorescence of the supernatant of the infected
cells that were treatedwith the peptide. Finally, IC50 was determined by
extrapolation of the results from various doses tested using a linear
equation. The experiment was repeated at least twice with a similar
result each time.
2.5. Quantitative real-time PCR assay
The inhibition of viral matrix gene replication of the peptides was
detected by quantitative real-time PCR as reported previously [19,20].
Brieﬂy, inﬂuenza A/Puerto Rico/8/34(H1N1) virus at 100 TCID50 was in-
cubated with peptides at 37 °C for 30min. Then the virus–peptide mix-
ture was added to the cells in 6-well plate and absorbed for another
30 min. After absorption, cells were washed twice with PBS to remove
unabsorbed virus, followed by the addition of serum free DMEMsupple-
mented with 1 mg/L TPCK-trypsin and 0.2% BSA. At 24 h post-infection,
the total RNAwas extractedwith TRIzol reagent (Invitrogen), RNA qual-
ity and quantity were determined by the UV spectrophotometer
(Merinton SMA1000, US). The total RNA was reverse transcribed into
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an ABI7500 PCR instrument (Applied Biosystems, US) with the SYBR
Premix Ex Taq as the manufacturer's instruction. Inﬂuenza A Matrix
protein gene expression was normalized to GAPDH gene, which stably
expressed in MDCK cells. Fold changes in gene expression were calcu-
lated using a classical 2−ΔΔCT method. Ribavirinwas employed as a pos-
itive control which was added at the concentration of 25 mg/L post-
infection and the real-time PCR assay was conducted simultaneously
to the cell treated with the peptides as described above. All samples
were run in triplicate. The primer sequences used for speciﬁc genes
are listed in supplementary material of Table 1. All experiments were
carried out in triplicate. Statistical signiﬁcance of the data was deter-
mined by one-way ANOVA method using SPSS software. Statistical
signiﬁcance was deﬁned as p b 0.05 (*p b 0.01, **p b 0.001).
2.6. MTT assays
The cytotoxicity of the peptides on MDCK cells was measured using
the MTT assay. Cells (1 × 104/well) were seeded in 96-well plates and
grown overnight, then the medium was replaced with fresh medium
containing serially diluted peptides and the cells were further incubated
at 37 °C with 5% CO2 for 48 h. The culture medium was removed and
replaced with 100 μL 0.5 mg/mL 3-(4,5-dimethylthiozol-2-yl)-3,5-
dipheryl tetrazolium bromide solution and incubated at 37 °C for 4 h.
Then the supernatants were discarded and 150 μL of dimethyl sulfoxide
(DMSO)was added to eachwell. The stained formazan product was de-
termined spectrophotometrically at 570 nmon a GENios Promicroplate
reader (Genios Pro Tecan, US).
2.7. Measurement of the inhibitory activity on the entry of
VSVG pseudovirus
The VSV pseudovirus was constructed by using VSV-glycoprotein
encoded plasmid and HIV backbone plasmid (pNL4-3.luc.R−E−). The
protocol is similar to that of inﬂuenza A pseudovirus. To test the inhib-
itory activity of these peptides against VSVG pseudovirus, MDCK cells
(1 × 104/well) were seeded in 96-well plates and grown overnight.
The peptides were serially two-fold diluted from 100 to 3.12 mg/L in
culture medium and then incubated with equal volume of pseudo-
typed particles at 37 °C for 30 min. Subsequently, the virus–peptide
mixture was transferred into the MDCK cells and incubated for 48 h at
37 °C before performing luciferase assay as described above.
2.8. Hemagglutination inhibition (HI) assay
The HI assay was employed to evaluate the inhibitory effects of the
peptides on viral adsorption into target cells. HI tests were performed
using 4 times of the HA units (HAU) of H5 standard antigen per well
(25 μL) in V-bottomed 96-well micro plates. An equal volume (25 μL)
of peptides started from 200 mg/L of two-fold serial dilution in PBS
was then added into the plate. Subsequently, 50 μL of chicken erythro-
cytes (0.5% v/v in PBS) was added to each well. An equal volume of
HA1 antiserum (25 μL, 4HAU) was used as a positive control, whileTable 1
IC50 of peptides against inﬂuenza A viral strains (mg/L).
Peptide H1N1a H3N2a H5N1b
C12-OOWO 8.48 ± 0.74 7.22 ± 0.67 9.03 ± 0.63
C12-KKWK 7.30 ± 1.57 6.14 ± 1.45 12.57 ± 3.77
Ribavirinc 3.23 ± 0.77 4.20 ± 2.42 NTd
CL-385319 NT NT 0.37 ± 0.12
a A/Puerto Rico/8/34 (H1N1) andAichi/2/68 (H3N2). Datawere acquired from the virus
titer reduction assay.
b H5N1 pseudovirus. Data were obtained from the luciferase assay.
c Ribavirin and CL-385319 were used as positive controls.
d Not test (NT).PBS as a negative control. The hemagglutination reaction results were
read after incubation for 1 h at room temperature. The experiment
was independently repeated three times, and each timewith four paral-
lel measurements. Both H5 standard antigen and antiserum were
provided by Haerbin Veterinary Research Institute, China.
2.9. Neuraminidase inhibition assay
Inﬂuenza virus NA activitywas assayed by quantifying the ﬂuorescent
product resulting from the cleavage of the substrate of [4-MU-NANA;
2-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid sodium] by
neuraminidase of the virus. The NA inhibition assay was conducted
using NA from inﬂuenza A/Puerto Rico/8/34(H1N1) virus as described
previously [21]. Brieﬂy, 30 μL inﬂuenza virus solutions was added to a
96-well black plate and mixed with 10 μL two-fold diluted peptides
ranging from 200 to 0.39mg/L to react for 15min at room temperature.
Then added 30 μL substrate dissolved in dilute buffer (33 mmol/L MES
(pH 3.5) and 4 mmol/L CaCl2) at a ﬁnal concentration of 20 μM and
30 μL H2O, and the mixtures were further incubated for 1 h at 37 °C in
the dark. The reaction was terminated with 150 μL 34 mM NaOH
(83% ethanol) and the ﬂuorescence of the mixture was recorded at
the excitation wavelength of 340 nm and emission wavelength of
440 nm.
Inhibitory activity %ð Þ ¼ Fvirus−Fsample
 
Fvirus−Fsubstrateð Þ
 100%
where Fvirus is the ﬂuorescence of the inﬂuenza virus control (virus,
buffer and substrate), Fsubstrate is the ﬂuorescence of the substrate con-
trol (buffer and substrate), and Fsample is the ﬂuorescence of the tested
samples (virus, sample solution and substrate). Finally, IC50 was deter-
mined by extrapolation of the results from various doses tested using
a linear equation. The experiment was repeated at least twice with a
similar data each time.
2.10. Hemolysis inhibition assay
Chicken red blood cells (cRBCs) were washed twice with PBS and
re-suspended to make a 2% (v/v) suspension in PBS, which was stored
at 4 °C until use. 100 μL of compound diluted in PBS was mixed with
an equal volume of the inﬂuenza virus A/PR/8/34 (H1N1) strain
(107 TCID50/mL) in a 96-deepwell plate. After incubating the virus–
compoundmixture at room temperature for 30min, 200 μL of 2% chick-
en erythrocytes pre-warmed at 37 °Cwas added. Themixturewas incu-
bated at 37 °C for another 30min. To trigger hemolysis, 100 μL of sodium
acetate (0.5 M; pH 5.0) was added andmixedwell with the erythrocyte
suspension and incubated at 37 °C for 15 min. To separate nonlysed
erythrocytes, plates were centrifuged at the end of incubation at
3000 rpm for 5 min. 200 μL of supernatant was transferred to another
ﬂat-bottom 96-well plate. The OD540 was read on a microtiter plate
reader.
2.11. The antiviral activity of the peptides against H274Y mutation virus
The procedurewas adopted as the same as abovementioned. Brieﬂy,
MDCK cells were seeded into a 96-well plate at 2 × 104 per well and
incubated overnight until grown up to conﬂuent. Inﬂuenza strain of
A/Puerto Rico/8/34 (H1N1) with H274Y mutation virus at 100 TCID50
was mixed with peptides in 2-fold dilution and incubated at 37 °C for
30 min. Subsequently, the virus–peptide mixtures were added to the
cells and incubated for another 30 min. Then cells were washed twice
with PBS to remove unabsorbed virus, followed by the addition of
DMEM supplemented with 1 mg/L TPCK-trypsin and 0.2% BSA. At 24 h
post-infection, the cells were immobilized with 80% pre-cooled
acetone for 10 min and then viral replication was determined by
measuring the levels of inﬂuenza virus nucleoprotein (NP) using an
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protection was calculated as [1 − (mean OD450compound − mean
OD450medium) / (mean OD450DMSO − mean OD450medium)] ×
100%, where mean OD450compound, mean OD450medium, and mean
OD450DMSO refer to the absorbance (optical density at 450 nm
[OD450]) of compound- and virus-containing samples, the absorbance
of no-virus control samples, and the absorbance of DMSO- and virus-
containing. Oseltamivir (Tamiﬂu) was used as a positive control with
IC50 value of 0.33 ± 0.037 mg/L, while the IC50 value for WT of
Inﬂuenza strain of A/Puerto Rico/8/34 (H1N1) was 0.017 ± 0.002 mg/L.
2.12. Statistical analysis
Graph Pad Prism 5 (San Diego, CA) was used to determine the half
cytotoxic concentration (CC50) and half inhibitory concentration (IC50)
values of peptides. All IC50 and CC50 values were calculated as the
means ± standard error of the mean (SEM) from triplicate assay from
at least three separate experiments. Statistical signiﬁcance of the data
was determined by independent test or one-way ANOVA method
using SPSS software.
3. Results
3.1. Peptide C12-KKWK and C12-OOWO display an antiviral activity
toward pseudo-inﬂuenza A virus
The “entry inhibitor” screening program was initiated by using
a pseudovirus based approach, of which the H5N1 inﬂuenza A
pseudovirus was constructed by employing the plasmids encoding
hemagglutinin glycoprotein (HA) and neuraminidase protein (NA) of
A/Thailand/Kan353/2004, and the antiviral effect was evaluated by
measuring the inhibitory effect on the infection of H5N1 pseudovirus
[14]. Upon screening our previously designed membrane-active
lipopeptide library [15], two “hits” of C12-KKWK and C12-OOWO
possessing the antiviral activity were identiﬁed. The preliminary results
in Table 1 showed that both C12-KKWK and C12-OOWO displayed a
good inhibitory effect with IC50 values of 12.57 ± 3.77 and 9.03 ±
0.63 mg/L, respectively.
3.2. C12-KKWK shows a potent antiviral activity against inﬂuenza A
viral strains
The antiviral activity of C12-KKWK and C12-OOWO was further
assessed by testing the viral strains of inﬂuenza A/Puerto Rico/8/34
(H1N1) and A/Aichi/2/68 (H3N2) with a virus titer reduction assay
[22]. The inhibition of viral replication was evaluated by measuring
the enzymatic activity of neuraminidase, a method employed for deter-
mining the virus titer in the supernatant [23]. The resultantﬂuorescenceFig. 1. The antiviral activity of C12-KKWK and C12-OOWO against inﬂuenza A/Puerto Rico/8/34
A/Puerto Rico/8/34 virus at 100 TCID50 for 30min, and subsequently, the virus–peptidemixture
and added serum free DMEMmedium supplemented with 1 mg/L TPCK trypsin and 0.2% BSA.of the mixture was recorded at the excitation wavelength of 340 nm
and emission wavelength of 440 nm. As a result, the IC50 values of
C12-KKWK and C12-OOWO were 7.30 ± 1.57 and 8.48 ± 0.74 mg/L
respectively against A/Puerto Rico/8/34 strain, and 6.14 ± 1.45 and
7.22 ± 0.67 mg/L against A/Aichi/2/68 (H3N2) strain (Table 1).
In parallel to the measurement of the enzymatic activity of neur-
aminidase, the antiviral activity against inﬂuenza A/Puerto Rico/8/34
(H1N1) was further conﬁrmed by using a quantitative RT-PCR (Fig. 1).
As reported, inﬂuenza matrix protein directly reveals to virus replica-
tion [24], we then inspected the mRNA levels of M protein after treat-
ment with peptides. The results displayed a dramatically reduced
level of mRNA expression on treatment with both C12-KKWK and
C12-OOWO (Fig. 1), consistent with the results observed from the
neuraminidase activity assay.
The initial results inspired us for a further speculation that whether
these peptides would be able to inhibit the replication of drug-resistant
viral strain. We then tested the antiviral activities of these peptides
against inﬂuenza strain of A/Puerto Rico/8/34 (H1N1) with H274Y mu-
tation, an inﬂuenza A (H1N1) virus with H274Y neuraminidase muta-
tion which is known for its resistance to neuraminidase inhibitor of
Oseltamivir [25]. As a result, by treatment of virus with peptides similar
to that in CPE inhibition assay, the levels of inﬂuenza virus nucleopro-
tein (NP) were measured by using enzyme-linked immunosorbent
assay (ELISA) to determine the antiviral effect. The IC50 values for each
peptide were 8.692 ± 1.125 mg/L (C12-KKWK), 3.945 ± 0.374 mg/L
(C18-KKWK), and 3.075 ± 1.094 mg/L (C20-KKWK) respectively,
which are similar to the results obtained from other assays.3.3. C12-KKWK is unable to inhibit the entry of vesicular stomatitis
(VSV) pseudovirus
Nextwe then investigated how the C12-KKWKexerted its inhibitory
effects on IAV. In this study, the pseudo-inﬂuenza A viruswas construct-
ed by encoding HA and NA plasmids of IAV into HIV backbone. Hence,
the antiviral activity of these peptides may result from the interaction
with either HA, NA glycoprotein of inﬂuenza A virus or HIV backbone.
Given the same rout of endocytosis in their steps of infections, we
employed vesicular stomatitis virus (VSV) as a control to study the pos-
sible target of these lipopeptides. The vesicular stomatitis pseudovirus
wasprepared by encodingVSV-glycoprotein plasmid intoHIV backbone
similar to that of IAV pseudovirus, and then was employed to evaluate
the inhibitory effect of C12-KKWK.
The results in Fig. 2 showed that C12-KKWK was unable to signiﬁ-
cantly reduce the infectivity of VSV pseudovirus onMDCK cells, indicat-
ing theunlikeness of theHIV backbone as the target of C12-KKWK. Thus,
the anti-IAV of these peptides may result from the interaction with HA
or NA by which to exert the anti-inﬂuenza A virus effect.(H1N1) determined by quantitative real-time PCR. The peptides were pre-incubated with
was transferred to the cells for another 30min. Then the cells werewashed twicewith PBS
At 24 h post-infection, the matrix gene was detected by quantitative real-time PCR.
Fig. 2. Inhibition of the infectivity of VSVG pseudoviruses by C12-KKWK. The VSV
pseudovirus was constructed by using VSV-glycoprotein encoded plasmid similar to that
of H5N1 pseudovirus.2 The peptides were serially two-fold diluted from 50 to 1.56 mg/L
in culture medium and then incubated with equal volume of pseudo-typed particles at
37 °C for 30 min prior to transferring into the MDCK cells and subsequently incubated
for 48 h at 37 °C before performing luciferase assay as described previously.
Fig. 3. Hemolysis inhibition assay. C12-KKWK in PBS was mixed with an equal volume of
the inﬂuenza virus A/PR/8/34 (H1N1) strain (107 TCID50/mL) in a 96-deepwell plate, and
200 μL of 2% chicken erythrocyteswas then added. Themixture was incubated at 37 °C for
another 30 min, following addition of 100 μL of sodium acetate (0.5 M; pH 5.0) to trigger
hemolysis. The mixture was incubated at 37 °C for 30min for HA acidiﬁcation and hemo-
lysis, and subsequently, the plateswere centrifuged and the supernatantwasmonitored at
OD540 on a microtiter plate reader.
Fig. 4. Neuraminidase inhibition assay of C12-KKWK. Inﬂuenza virus NA activity was
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under the low pH condition
A critical step for virus entry is themembrane fusion induced by low
pH. To investigate whether C2-KKWK inhibits the conformational
changes of HA2 subunit, thereby blocking the fusion of viral-cell mem-
brane, we then carried out a hemolysis inhibition assay under the acidic
condition. As shown in Fig. 3, when exposure themixture of chicken red
blood cells (cRBCs) with inﬂuenza virus strain of A/PR/8/34 (H1N1)
(107 TCID50/mL) to the twofold serial dilutions of C12-KKWK in acidic
buffer (pH = 5), the hemolysis of cRBCs was apparently inhibited in a
dose-dependent manner, suggesting that interruption of the conforma-
tional changes of HA2 triggered by low pHwould be the possible mech-
anism of C12-KKWK, by which to block the entry of virus (Fig. 3).
3.5. C12-KKWK is unable to inhibit the activity of neuraminidase (NA)
According to the inﬂuenza A pseudovirus construction model in
this study, it was reasonably deduced that the antiviral activity of
C12-KKWK may result from the interactions with HA or NA, or both.
To explore the possible target, a neuraminidase inhibition assaywas ap-
plied to evaluate the antiviral effect and to determine the possible target
of C12-KKWK. The assay was carried out by quantifying the ﬂuorescent
products resulting from the cleavage of the substrate of [4-MUNANA;
2-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid sodium] by
NA [26]. The NA was derived from inﬂuenza A/Puerto Rico/8/34
(H1N1) virus as described previously [14]. The results in Fig. 4 showed
that only less than 20% inhibitory effects were observed, suggesting
that C12-KKWK was unable to inhibit the NA activity signiﬁcantly.
Thus, the most possible target of C12-KKWK would be the hemaggluti-
nin (HA) by which to block the entry of virus into host cells.
3.6. Possible interactions between C12-KKWK and receptor-binding
site of HA
The HA is located on the surface of the virus as a homotrimer with
each monomer consisting of two subunits, HA1 and HA2. In the events
of virus entry, the HA1 subunit is responsible for binding the virus to
host cell of sialic acid-containing receptors, while the HA2 subunit is
responsible for fusion [27]. To demonstrate the interactions between
C12-KKWK and the possible receptor-binding site of HA, we then2 Peptide C12-KKWK that inhibits the infectivity of H5N1 pseudovirus at various
concentrations was employed as a comparison. Each data was expressed as the mean of
three independent replicates. CL-385319 at 50 μM was used as a positive control, while
wells without peptides as a negative control.carried out a hemagglutination inhibition (HI) assay by observing the
inhibitory effect of agglutination of chicken erythrocytes and to deter-
mine whether HA1 would be the potential target of these lipopeptides
[21]. The experiment procedure was adopted from previously reported
paper [21], and the results showed that C12-KKWKwasunable to inhib-
it the agglutination of red blood cells [data not shown], implying the
unlikeness of sialic acid binding site on HA1 subunit as the binding of
C12-KKWK binding site.
To further assess the potential target of C12-KKWK, we then per-
formed a docking simulation by using Sybyl 2 software. The HA structure
used was that of 4CQP (H5N1) obtained from the Protein Data Bank
(PDB). The total score of the interaction between C12-KKWK and HA2
was 8.7277, which is higher than 6.2342 of the interaction between
C12-KKWK and HA1. As shown in the possible interaction of the
HA2-C12-KKWK complex (Fig. 5), the residues of Gln 62, Leu 89, Thr 93
and Thr 107 form strong intramolecular hydrogen bonding with lysins
of C12-KKWK. In addition, the residues of Ile 56 and Ile 55 are observed
to be close to the lipid chainwherehydrophobic interactionswould occur.
3.7. The antiviral activity of C12-KKWK is improved by structure and
activity relationship study
Next, we studied the relationships between peptide structures and
the antiviral activities of these peptides. Considering the critical role of
lipophilicity in the generation of antimicrobial peptides, we then varied
the lengths of lipid tail to search for more potent viral entry blockers.assayed by quantifying the ﬂuorescent product resulting from the cleavage of the sub-
strate of [4-MU-NANA; 2-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid sodium]
by NA. After reaction for 1 h at 37 °C in the dark, the ﬂuorescence was recorded at the ex-
citation wavelength of 340 nm and emission wavelength of 440 nm. The experiment was
independently repeated at least twice. Peramivir was used as a positive control, which
showed 86.7% inhibition at 3.9 mg/L.
Fig. 5. The docking simulationwas performed in Sybyl 2.0 software. TheHA structure used
was that of 4CQP (H5) obtained from the Protein Data Bank (PDB). As a consequence of
docking, the total score was 8.7277 between the interaction of C12-KKWK and HA2,
while of 6.2342 was obtained between C12-KKWK and HA1. A and B show a possible
interaction of the HA2-C12-KKWK complex, where C12-KKWK is recognized by the active
pocket of HA2. C is the 3D structure of the whole HAmolecule (gray) and the binding site
where the lipopeptide (blue) is located.
Table 2
Inhibitory effect of designed lipopeptides.
Sequence IC50 (mg/L) a CC50 (mg/L) b SI c
C6-OOWO N50 NT d NA d
C8-OOWO N50 NT NA
C10-OOWO 57.81 ± 0.29 NT NA
C12-OOWO 9.03 ± 0.63 124.42 ± 1.26 13.77
C14-OOWO 8.21 ± 0.17 105.43 ± 1.84 12.84
C16-OOWO 7.35 ± 0.90 101.40 ± 0.92 13.79
C18-OOWO 4.18 ± 0.20 64.30 ± 2.08 15.38
C20-OOWO 2.14 ± 0.10 47.31 ± 0.57 22.10
C6-KKWK N50 N200 NA
C8-KKWK N50 N200 NA
C10-KKWK 56.18 ± 11.90 N200 NA
C12-KKWK 12.57 ± 3.77 137.00 ± 4.10 10.89
C14-KKWK 9.96 ± 2.59 115.90 ± 0.66 11.63
C16-KKWK 8.81 ± 2.95 103.50 ± 1.39 11.74
C18-KKWK 4.68 ± 0.90 74.73 ± 5.49 15.93
C20-KKWK 2.72 ± 0.30 53.20 ± 0.66 19.53
a Inhibitory activities against A/Thailand/Kan353/2004 H5N1 inﬂuenza A pseudovirus
infection of MDCK cells. Data was acquired from the luciferase assay.
b Cytotoxicities against MDCK cells tested with MTT assays.
c Selective index was acquired by using CC50 divided by IC50.
d Not test (NT).; not available (NA).
2349W. Wu et al. / Biochimica et Biophysica Acta 1848 (2015) 2344–2350The sequences and activities are listed in Table 2. As a result, peptides
C20-KKWK and C20-OOWOwere proved to be themost active peptides
with IC50 values of 2.72 ± 0.30 and 2.14 ± 0.10 mg/L, respectively.
3.8. The cytotoxicities of these peptides are associated with the lengths of
lipid chains
A signiﬁcant concern in the development of peptide drug is the
toxicities toward mammalian cells. To assess the discrimination ability
of these peptides between mammalian cells and pathogenic viruses,
MTT assay was employed to test the cytotoxicities of selected peptides
against MDCK cells [14]. The data in Table 2 showed that the cellular
toxicities of these peptides were highly associated with the lengths of
lipid tails, of which C20 fatty acid substituted peptides appeared to be
the most toxic peptides, while the peptides consisting of shorter lipid
chainswere less toxic. Therefore, C20-OOWO and C20-KKWKwere rep-
resented as the most toxic peptides with CC50 values of 47.31 ± 0.57
and 53.20 ± 0.66 mg/L, respectively. Overall, these results were consis-
tent with our previous observations that a higher hydrophobicity is
sometimes accompanied with a higher cellular toxicity (Table 2) [15].4. Discussion
The rapid emergence of new antiviral resistance strains to currently
available drugs such as adamantanes or neuraminidase inhibitors has
created an urgent need for new antiviral targets and new therapeutics
for the prevention and treatment of inﬂuenza virus infections. In this
paper, we identiﬁed a super short lipopeptide of C12-KKWK and its de-
rivatives effectively inhibiting the entry of inﬂuenza A virus into host
cells. The lipopeptides being selected as viral “entry blockers” are main-
ly based on the following facts that (a) in addition to antimicrobial activ-
ities, many peptides are also able to inhibit the replication of viruses,
thereby making them potential candidates as potent antivirals [28,29];
(b) many hydrophobic lipids or polymer-containing agents such as sial-
ic acid-containing lipids [30], polymers [31], sialic acid-conjugated den-
dritic polymers [32,33], and fatty acid-containing sialic acidmimics [34]
show antiviral activities that have been developed as viral entry
blockers; and (c) the clinically used HIV entry inhibitor of enfuvirtide
(Fuzeon) has shown the powerful potential of peptide drugs in the pre-
vention of viral infections [35]. In addition, the super small size, less im-
mune response and easy to access of these peptides also intrigued us for
this study.
The glycoproteins of hemagglutinin (HA) and neuraminidase (NA)
are found on the inﬂuenza A viral particle surface: HA involves binding
of the virion to target cells and subsequently injecting the viral genomic
material into the target cell, while NA is associated with the release of
progeny virions from infected cells [36]. These proteins are usually the
targets for antiviral drugs to intervene. By employing a viral entry inhi-
bition assay, we identiﬁed that C12-KKWK and its derivatives were able
to block the entry of IAV, while unable to block the entry of VSV-G. The
mechanism-of-action study indicated that the antiviral effects of these
peptidesmay result from the interactionwith HA, but not NA. However,
the detailedmechanisms bywhich to block the viral entry are not yet to
be fully understood. Our preliminary studies suggested that C12-KKWK
may not act on sialic acid binding site of HA1, instead, it might interact
with HA2 subunit to inhibit the conformational changes of HA2 thereby
blocking the process of membrane fusion. However, this study cannot
exclude the possibility that C12-KKWK may also act on a non-speciﬁc
receptor on HA thereby inhibiting the entry of viruses [37].
The structure and activity relationship study showed that both the
antiviral activity and cytotoxicity were enhanced alongside the increase
of lipid chain, aswell as the selective indices, indicating a useful strategy
to optimizing the structures of these peptides in our future research.
2350 W. Wu et al. / Biochimica et Biophysica Acta 1848 (2015) 2344–2350In conclusion, by employing a pseudovirus based screening
approach, in this study, we identiﬁed a group of IAV “entry blockers”
with only four amino acid residues. Although the anti-IAV potencies of
these peptides are in the range of micro-molar concentrations, their
structures could be improved by chemical modiﬁcations. More impor-
tantly, these compounds possess a different mechanism from current
anti-IAV drugs in clinical practice which will encourage us for further
investigations.
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